The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model.
The partial dopamine agonist terguride (transdihydrolisuride) administered to four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned hemiparkinsonian monkeys (at a dose of 4 mg/kg orally) induced marked contralateral turning that lasted 3.5 h. The 6-n-propyl derivative of terguride (proterguride) given to two monkeys (at a dose of 0.4 mg/kg orally) caused contralateral turning which lasted for more than 24 h but produced side effects such as dyskinesia and stereotype. After terguride treatment, cerebrospinal fluid concentrations of 3-methoxy-4-hydroxy-phenylglycol (MHPG) were increased, whereas concentrations of the metabolites dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA) were not significantly altered.
Brücke
T
T
National Institutes of Health, Bethesda, MD 20892.
Bankiewicz
K
K
Harvey-White
J
J
Kopin
I
I
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D004195:Disease Models, Animal; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D008090:Lisuride / Q000031:analogs & derivatives / Q000494:pharmacology*; D008252:Macaca fascicularis; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D011725:Pyridines; D011954:Receptors, Dopamine / Q000502:physiology*
D004873:Ergolines; D011725:Pyridines; D011954:Receptors, Dopamine; C006208:dironyl; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008090:Lisuride